clinical trial · NCT05695976
GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
GlioblastomaGlioma, Malignant
brief summary
The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.
started
Apr 18, 2023
primary completion
Jan 1, 2029
completion
Jan 1, 2029
last updated
May 28, 2025
official title
A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol